Lv2
140 积分 2022-09-06 加入
Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA EGFR Mutated NSCLC With High Risk (APPOINT)
1个月前
已完结
Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation
1个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
3个月前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
4个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
9个月前
已完结
Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease
10个月前
已完结
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
11个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1年前
已完结
93P Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA
1年前
已关闭
皖公网安备34019202002308
